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Abstract
The worldwide prevalence of hepatitis C virus (HCV) 
infection in children is 0.05%-0.4% in developed 
countries and 2%-5% in resource-limited settings, 
where inadequately tested blood products or un-sterile 
medical injections still remain important routes of 
infection. After the screening of blood donors, mother-
to-child transmission (MTCT) of HCV has become the 
leading cause of pediatric infection, at a rate of 5%. 
Maternal HIV co-infection is a significant risk factor for 
MTCT and anti-HIV therapy during pregnancy seemingly 
can reduce the transmission rate of both viruses. 
Conversely, a high maternal viral load is an important, 
but not preventable risk factor, because at present no 
anti-HCV treatment can be administered to pregnant 
women to block viral replication. Caution is needed in 
adopting obstetric procedures, such as amniocentesis or 
internal fetal monitoring, that can favor fetal exposure 
to HCV contaminated maternal blood, though evidence 
is lacking on the real risk of single obstetric practices. 
Mode of delivery and type of feeding do not represent 
significant risk factors for MTCT. Therefore, there is no 
reason to offer elective caesarean section or discourage 
breast-feeding to HCV infected parturients. Information 
on the natural history of vertical HCV infection is 
limited. The primary infection is asymptomatic in 
infants. At least one quarter of infected children shows 
a spontaneous viral clearance (SVC) that usually 
occurs within 6 years of life. IL-28B polymorphims and 
genotype 3 infection have been associated with greater 
chances of SVC. In general, HCV progression is mild or 
moderate in children with chronic infection who grow 
regularly, though cases with marked liver fibrosis or 
hepatic failure have been described. Non-organ specific 
autoantibodies and cryoglobulins are frequently found 
in children with chronic infection, but autoimmune 
diseases or HCV associated extrahepatic manifestations 
are rare. 
Key words: Hepatitis C virus; Vertical transmission; Risk 
factors; Spontaneous viral clearance; Disease progression; 
Pediatrics
2016 Hepatitis C Virus: Global view
TOPIC HIGHLIGHT
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Approximately 5% of exposed infants acquire 
hepatitis C virus (HCV) infection from the mother. 
Several correlates of vertical transmission have been 
identified, but no preventive intervention is available. 
Spontaneous viral clearance takes place in 25% 
of infected children within 6 years of age. Chronic 
infection has a mild/moderate course in the majority 
of children, though severe liver damage may develop. 
The new direct acting antiviral agents open exciting 
therapeutic perspectives for HCV infected children and 
offer an immediate opportunity to prevent the vertical 
transmission by reducing the burden of infected women 
of child-bearing age.
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INTRODUCTION
Hepatitis C virus (HCV) is a small, enveloped, single-
strand RNA virus of the Flaviviridae family, which is 
transmitted via parenteral route[1]. In a high proportion 
of infected subjects the virus can persist and give rise 
to chronic liver disease, cirrhosis and hepatocellular 
carcinoma. 
The total global prevalence of HCV infection is 
estimated to be 2%-3%, affecting approximately 
160 million chronically infected individuals worldwide, 
with highly variable local prevalence rates between 
countries and within countries[2]. A recent literature 
review[3] described lower total global numbers (115 
million HCV seropositive subjects, 80 million viremic 
infections), with a prevalence (1.6%) that might 
be decreasing. However, in other analyses the total 
disease burden is expected to increase in the next 
decade[4,5]. In fact, several risk factors have changed 
after the discovery of the virus. First of all, with the 
screening of blood donors the risk of contracting HCV 
from infected transfusions or blood products became 
extremely rare in resource-rich countries, where, 
conversely, needle exchange among intravenous 
drug users remains a paramount mode of horizontal 
transmission. Un-sterile medical injections and surgical 
procedures still remain a threat in a few regions of 
Africa[6]. Deaths due to long-lasting infections and 
immigration from high endemic areas may also play a 
role on the epidemiology of HCV infection, whereas the 
impact of antiviral treatments is irrelevant. 
Few analyses have outlined the age distribution of 
HCV infection: a global number of 11 million anti-HCV 
positive children (< 15 years) has been calculated, 
with 5 million viremic infections[3]: such a surprising 
high proportion of infected children with spontaneous 
viral clearance (SVC) is presumably due to the intrinsic 
limits of these studies that can only partially reflect the 
real burden of infection. 
Before the universal screening of blood products, 
pediatric HCV infection was predominantly due 
to iatrogenic transmission; then, mother-to-child 
transmission (MTCT) became the leading source 
of infection in childhood in developed countries. 
Notably, the increased safety of blood products and 
injection equipment also reduced the number of HCV 
infected women of childbearing age and consequently 
the number of vertical infections and the relative 
distribution of single genotypes. For instance, in 
Italy the total number of pediatric infections has 
been decreasing as well as the percentage of the 
transfusion-associated type 1b genotype, while the 
relative percentages of genotype 3 or 4 infections have 
been increasing[7]. On the other hand, many cases of 
hepatitis C in children and adolescents from resource-
limited settings are still due to inadequately screened 
blood products and/or parenteral transmission[8,9]. 
These variations in risk factors account for the different 
prevalence of pediatric HCV infection that ranges from 
0.05% to 0.36% in developed countries and from 1.8% 
to 5% in the developing world[10-12]. 
This review gives insights into the most relevant 
data about the risk of vertical HCV infection and 
correlates of transmission and highlights the evolution 
of the infection in children and adolescents. 
HCV INFECTION DURING PREGNANCY
The prevalence of HCV infection in pregnant women 
mirrors that of the general population: ranging from 
0.5%-2% in high-income countries to 5%-15% 
in some developing countries[13-16]. Most infected 
women do not develop HCV-mediated clinical 
manifestations during pregnancy, although an increase 
in gestational cholestasis has been described in some 
studies[17-19]. Indeed, there is a decrease of serum 
alanine aminotransferase (ALT) levels, a marker of 
liver cytolysis, in the advanced phase of pregnancy 
with concomitant increase in HCV viral load[16,20-22]. 
Conversely, in the post-partum period there is a 
rebound in ALT levels and a reduction in viral load[23-25]. 
Gestation is characterized by a down regulation of 
the immune responses[26], in particular of the T cell-
mediated reactivity[27] with expansion of regulatory 
T cells[28], presumably to prevent maternal immune 
aggression against the fetus. This impaired cellular 
response on one hand may result in a reduced 
immune-mediated liver damage; on the other hand, it 
may favor the viral replication. In contrast, in the post-
partum period the T-cell mediated cytotoxicity against 
HCV epitopes would recover with consequent decline 
in viral burden and rebound of liver injury. 
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A large observational study concluded that infants 
born to women with HCV infection appear to be at risk 
for poor birth outcomes, such as preterm delivery, low 
birth weight and congenital anomalies[29]. However, 
most studies did not evidence any increase in 
obstetric complications in HCV infected women[16,30,31]. 
Concomitant diseases, such as coagulation disorders 
or digestive tract malformations were also noticed in 
some vertically infected children, but these disorders 
do not appear HCV-related[32].
Mother-to-child transmission of HCV
The vertical HCV transmission rate is estimated to be 
about 5%, ranging from 3% to 10%[12,15,33-44]. These 
variations are mostly due to the small sample size of 
some investigations, differences in diagnostic criteria, 
population’s risk factors, type of study (retrospective or 
prospective), and duration of follow-up. The diagnosis 
of HCV infection in exposed infants is complicated 
by passively acquired maternal antibodies. These 
usually wane by 12 mo of age, but sometimes persist 
longer[45]. Furthermore, the first PCR assays were 
poorly standardized with consequent limits of sensitivity 
and specificity[46,47].
HCV can infect placental cells[48]. In addition, 
maternal cells can cross the placenta and reach 
the fetus. Therefore, fetal exposure to HCV would 
take place more frequently than actual in utero 
transmission. Natural killer (NK) cells and NK T cells 
seem to play an important role in the clearance 
of acute HCV infection[49,50]. NK T cell and γδ T cell 
frequencies are higher in placenta from HCV-infected 
women and production of cytokines and cytotoxicity 
mediated by NK cells and NK T cells are increased in 
HCV-exposed placenta[51]. 
Vertical transmission takes place with every 
genotype. Studies on the quasispecies profile of HCV-
infected infants revealed a limited diversity[52-55], 
suggesting that only a restricted number of viral 
variants, not dominant in the mother, are involved in 
MTCT. Characterization of circulating viral quasispecies 
during and after consecutive pregnancies in two 
women revealed loss of some escape mutations in HLA 
class I epitopes during pregnancy, presumably due 
to reduced cytotoxic T lymphocyte control. This was 
associated with emergence of viruses with optimized 
replicative fitness, which were also found in their 
infected children[56]. 
When does HCV MTCT occur?
We documented that one third of exposed infants 
ultimately shown to be infected are HCV RNA positive 
in the first 3 d of life, demonstrating that early in 
utero infection may occur; the others mostly become 
HCV RNA positive in the second/third month of life[57]. 
Interestingly, the time of appearance of viremia is 
similar in children vertically infected with HIV-1. 
This would suggest that the relative percentages of 
children infected before, during or post-delivery with 
either virus are comparable. However, in contrast to 
HIV-1, mode of delivery and type of feeding have no 
significant impact on HCV MTCT rate. Furthermore, the 
risk of transmitting HCV to the offspring is lower than 
HIV-1, despite the higher maternal viral load of the 
former, attesting that the underlying mechanisms and 




Vertical transmission is virtually restricted to women 
with detectable viremia[33,36,39,44,58-62], even though 
anecdotal cases from mothers with undetectable 
viremia have been reported[36,38,63-65]. A clear association 
between maternal viral load and risk of vertical 
transmission has been demonstrated: the higher the 
viral burden, the greater the risk of infection for the 
offspring. However, there is a broad overlap in the HCV 
RNA levels between transmitting and non-transmitting 
mothers and no threshold value has been identified to 
precisely quantify the risk of transmission. 
HCV RNA is found in about 70% of seropositive 
pregnant women, but the percentage of viremic 
infections among antibody-positive women changes 
greatly in distinct geographical areas[2,3]: this might 
explain, in part, the different estimates of HCV MTCT 
rates from studies that did not take into consideration 
the maternal viremia. 
HCV can infect and replicate in PBMCs and a 
relationship was found between HCV RNA in PBMCs 
of pregnant women and vertical transmission[66]. In 
this view, the HLA concordance between mother and 
offspring might facilitate the persistence of maternal 
cells in the newborn blood and the infection of newborn 
target cells (see below). 
HCV/HIV-1 co-infection
The rate of HCV MTCT is increased when the mother 
is co-infected with HIV-1[35,37,39,41,67,68]; a recent meta-
analysis concluded that maternal HIV co-infection 
is the most important determinant of vertical 
transmission risk (adjusted odds ratio 2.56; 95%CI: 
1.50-4.43)[43]. The HIV-1-induced immunosuppression 
could lead to a higher HCV viral load, although this 
was not consistently observed[21]. In this context, 
when HIV/HCV co-infected pregnant women were 
treated with highly active antiretroviral therapy 
(HAART) the significant increase in HCV transmission 
disappeared[38,39]. It is worth noting that HIV-1 and 
HCV are mostly acquired independently from women 
with double infection, even though simultaneous 
transmission may occur.
Obstetric factors and rupture of membranes 
HCV RNA has been detected in amniotic fluid, although 
inconsistently[69]. Amniocentesis was considered a 
likely explanation for diamniotic twins discordant 
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study[82]. Another investigation on concordance degree 
in HLA-DRB1 locus revealed that a HLA mismatch 
between mother and child was a protective factor, 
suggesting that alloreactive immune responses are 
involved in preventing HCV vertical transmission; 
in addition, maternal HLA-DRB104 correlated with 
protection, while HLA-DRB110 in children was a risk 
factor[83]. Others found that HLA-Cw*07, -G*010401, 
-DRB1*0701, -DRB1*1401 and homozygosis for 
HLA-G 14bp deletion can be considered as risk 
factors for HCV vertical transmission; on the contrary, 
protection was conferred by the HLA-DQB1*06, 
-G*0105N, -Cw*0602, DRB1*1104 and -DRB1*1302 
alleles[84]. The role of IL-28B polymorphisms on MTCT 
rate is irrelevant[60].
Cytokine gene polymorphisms, which affect the 
expression levels of the produced protein, were 
also investigated for TNF-α, interferon (IFN)-γ, 
IL-10, TGF-B1. No significant differences emerged 
between infected and uninfected children or between 
transmitting and non-transmitting mothers by 
comparing intermediate and low cytokine producers 
with high cytokine producers[83]. 
Other factors
Maternal age, number of pregnancies, prematurity, 
cigarette smoking, and alcohol intake have no 
significant impact on HCV MTCT rate. Discordant 
results were reported for Ⅳ drug use[42,72,85,86]. 
Notably, broadly reactive maternal neutralizing 
antibodies do not contribute to prevent vertical 
transmission[87,88].
A higher HCV transmission rate in females than 
in males emerged from a few studies[38,89]. Curiously, 
the same gender effect emerged for HIV[90,91] and 
human T-cell leukemia/lymphoma virus type Ⅰ[92]. 
One wonders whether differences between males 
and females in hormonal or genetic background can 
modulate their immune response and thus their 
susceptibility to a few viral infections.
NATURAL HISTORY OF VERTICALLY 
ACQUIRED HCV INFECTION 
The evolution of vertically acquired HCV infection is 
ill-defined, because there are few large prospective 
studies on children identified at birth and with 
prolonged follow-up, while the majority also include 
patients who acquired parenteral infections or who 
were referred to tertiary centers. Consequently, 
these analyses may underestimate the number of 
children with spontaneous clearance of infection and 
overestimate that of symptomatic children or with 
biochemical signs of hepatitis. 
Primary infection
At birth and in the first weeks of life HCV infected 
newborns are asymptomatic and without any evidence 
for HCV infection, as the needle punctured the sac 
of one fetus[70]. However, in other diamniotic twins, 
only one was infected but amniocentesis was not 
performed[71]. Procedures that allow contact between 
maternal and fetal blood, such as amniocentesis, are 
expected to increase the risk of HCV transmission, 
though the limited studies available do not support 
this hypothesis[39,68]. Internal fetal monitoring was 
linked to a higher transmission rate[39] and a significant 
increase was observed in women who underwent 
perineal or vaginal lacerations, whereas episiotomy 
was irrelevant[59]. The duration of rupture of membranes 
(ROM) was longer in mothers of infected infants 
vs uninfected infants[61,72]. This association also 
emerged by comparing a duration of ROM > 6 h[39] 
between transmitting and non-transmitting mothers. 
Antithetical results were reported by Delotte et al[68], 
who concluded that HCV infection does not appear 
to be a legitimate indication for modifying common 
obstetric practices.
Mode of delivery
Theoretically, elective caesarean section (CS) might 
reduce the HCV MTCT risk by preventing contact of 
the newborn with maternal blood during labor and 
infected genital secretions during the passage through 
the birth canal. Some studies observed a lower risk 
of infection in children born by CS[72-74]. However, 
the majority of targeted investigations, including 
the largest observational studies[20,36-38], consistently 
concluded that mode of delivery does not influence 
the HCV vertical transmission rate and such findings 
have been confirmed by a targeted meta-analysis[75]. 
Indeed, it is worth considering that elective CS might 
have protective effects in women with high viral load, 
a situation that has not been sufficiently analyzed. 
In fact, most expert recommendations or guidelines 
conclude that there is no reason to offer elective CS to 
HCV infected pregnant women[19,62,76-79]. 
Type of feeding 
The data concerning the viral content in breast milk 
are contradictory[39,64,72,80,81], presumably following the 
differences in maternal viral load, methods used or 
portion of milk studied. 
A few studies reported higher HCV transmission 
rates in breast-fed infants[64,72]. However, most results 
attest that type of feeding has no significant impact 
on the risk of HCV transmission[36-39,62,81]. Therefore, 
there is a consensus that breast-feeding should not be 
discouraged in HCV infected mothers[62,76-79]. However, 
these should consider abstaining from breast-feeding 
if their nipples are cracked or bleeding according to the 
Centers for Disease Control and Prevention[78]. 
Genetic background
Few studies addressed the role of genetic factors in 
HCV MTCT. Differences in HLA system between mother 
and infant did not affect HCV transmission in one 
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of liver damage[93,94]. Subsequently, some infants 
exhibit high ALT levels, while others maintain normal 
or almost normal levels[94-96]. In general, acute HCV 
infection does not cause disturbances in infants, 
whereas in adults it may have a severe or even fatal 
evolution; furthermore, on average, ALT levels are 
considerably lower in the former. 
Even if the fetal immune system can mount 
effector responses, e.g., against cytomegalovirus[97], 
no specific T cell responses against HCV were observed 
in umbilical cord blood samples of exposed children[98].
Spontaneous resolution of viremia 
In our large, prospective European study 20% of 
vertically infected children had a SVC by the age of 5 
years[99]; in the cohort of our patients prospectively 
followed from birth, 27% cleared circulating HCV RNA 
over a 10-year period[32], and Yeung et al[100] observed 
that viremia disappeared in 25% of infected children, 
in comparable proportion between vertical and 
transfusional infections. More pessimistic estimates 
emerged from other studies, e.g., loss of HCV RNA 
in 9%-11% of infected subjects[101,102]: these figures 
may be accounted for by the fact that also children not 
identified at birth were enrolled in the analyses. SVC is 
associated with biochemical remission of hepatitis and 
it usually occurs by 7 years of age[32,100,103]. Antiviral 
therapy should thus be postponed beyond the preschool 
age, unless in selected cases, in order to avoid useless 
treatments. Interestingly, children who reached SVC 
had higher ALT levels in the first two years of life when 
compared to those with persistent infection[32,95], as if a 
stronger cytolytic effect would mirror a more vigorous 
immune response ultimately resulting in resolution of 
infection. 
Understanding the mechanisms responsible for 
SVC plays a crucial role for development of future 
vaccines. Both viral and host factors have been 
associated with SVC, such as genotype 3 infection[32,95] 
or positive IFN-γ responses against structural and non-
structural recombinant HCV antigens[104]. Furthermore, 
children with the rs 12979860 single-nucleotide C/C 
polymorphism located on chromosome 19q13.13, 
upstream of the interleukin 28B gene, have a higher 
probability of SVC[105,106], particularly with genotype 
1 infection[60]. IL-28B is one of the three IFN-γ genes 
that code type Ⅲ IFNs. These elicit the transcription 
of interferon-stimulated genes that are responsible 
for antiviral activity. Therefore, variations in genes 
involved in the immune response against the virus 
influence the spontaneous clearance of HCV. The 
aforementioned marked differences in the percentage 
of viremic subjects in distinct areas of the world further 
support the importance of the genetic background in 
favoring the resolution of viremia, though even the 
different distribution of viral genotypes could have a 
role[3]. 
Humoral immunity 
A few HCV RNA-positive, antibody-negative asympto-
matic children have been described[60,65,94]. However, 
virtually all vertically infected children develop specific 
antibodies against HCV. These persist even after SVC, 
although a fraction of these subjects can serorevert 
after many years[32].
The presence of cross-reactive neutralizing anti-
bodies during the chronic phase of infection does not 
correlate with better control of viremia[88]. In contrast, 
the humoral response drives the evolution of viral 
quasispecies (see below). 
Chronic HCV infection
The chronic infection has a different clinical course in 
children as compared to adults. Every study highlights 
that HCV progression is minimal or mild in children, 
though severe hepatic damage may develop and liver 
transplantation may be required[12,13,44,95,96,99,101,102,107]. 
Hepatocellular carcinoma is extremely rare and, to our 
knowledge, it was described only in one adolescent 
with possible vertical infection[108]. Children grow 
regularly without variations from normal height 
and weight ranges[109], only a quarter develop 
hepatomegaly in the first decade of life[99], and they 
disclose mild variations in peripheral lymphocytes and 
neutrophils[110]. 
A broad range of ALT concentrations has been 
observed in vertically infected children: the majority 
shows modest alterations. ALT levels are highest in the 
first two years of life then decline[94]; from the practical 
point of view, they are not a reliable prognostic marker, 
because they are poorly predictive of the underlying 
liver damage. 
A wide spectrum of histopathological alterations 
has been found in the liver of children with vertical 
infection. The characteristic lesions of chronic hepatitis 
C described in adults, such a steatosis, sinusoidal 
and portal aggregates of lymphocytes, and bile duct 
abnormalities have been observed also in children. 
Based on signs of structural alterations, inflammatory 
activity, and necrosis, the grade of disease usually 
varies from minimal to moderate; however, a few 
children show variable degrees of fibrosis or, rarely, 
pictures of overt cirrhosis[94-96,107,111-113]. Liver biopsy 
is not a routine procedure in the management of 
HCV infected children; transient elastography may 
help, distinguishing the evolution of liver fibrosis over 
time[32].
Viral quasispecies
One of the most important characteristics of HCV 
is its capacity to mutate very quickly. In addition, 
it can impair both the innate and adaptive host’s 
immune response, e.g., by inhibiting the activation of 
dendritic cells, the IFN production, and by evading or 
exhausting the T cell responses[114]. The consequence 
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is a persistent infection with many viral variants 
(quasispecies) replicating simultaneously in each 
infected individual. 
The impact of the evolution of viral quasispecies 
on the course of pediatric HCV infection has been 
examined in several studies with contrasting results. 
We observed that children who developed hepatic 
damage had mono- or oligoclonal populations of viral 
variants, whereas heterogeneous viral quasispecies 
emerged in those with mild or no liver damage, 
in coincidence with the appearance of anti-HCV 
antibodies[55]. High ALT levels might be the result of a 
vigorous cell-mediated immune response against the 
virus, while normal ALT levels would result from an 
absent or weak cellular response in the presence of a 
robust humoral response; the latter could exert strong 
selective pressures leading to a broad spectrum of HCV 
quasispecies. A mechanism of long-lasting nucleotide 
invariability with purifying selection operating on the 
HVR1 has been confirmed[115]. However, others[54] 
found that changes in the HVR-1 sequence occurred 
irrespective of the ALT profile; indeed, the study 
population included only children > 1 year, whereas 
the diversification of the HCV population takes place 
between 6 and 12 mo after birth[52].
The importance of humoral response in determining 
the evolution of quasispecies is further supported by 
limited or no variations in a persistently seronegative 
child[65], in children and adults suffering from 
agammaglobulinemia[116], and in children with HIV-1 
co-infection whose humoral response is defective[53,117]. 
Extrahepatic manifestations
A wide array of extrahepatic manifestations has 
been associated with chronic HCV infection. Among 
these, mixed cryoglobulinemia is the most frequent in 
adults[118]. It is due to an unregulated clonal expansion 
of B-lymphocytes, which may give rise to membrano-
proliferative glomerulonephritis in one third of cases, 
to purpura, arthralgia, peripheral neuropathy and 
ultimately it may evolve in non-Hodgkin’s lymphoma. 
Mixed cryoglubulinemia had not been described in 
children. In our cohort of 45 children prospectively 
followed-up from birth, surprisingly we found that 
one third developed cryoglobulins at a median age 
of 6.6 years (range 2.0-13.3 years) and two affected 
adolescents initially exhibited C4 reduction and then 
developed mild persistent proteinuria[32]. In fact, 
membrano-proliferative glomerulonephritis may occur 
in children with chronic HCV infection[119,120].
Non-organ specific autoantibodies (NOSAs) are 
frequently detected in subjects with chronic hepatitis 
C, including children. Anti-liver-kidney microsomal 
type-1 (LKM-1) antibody seems peculiar of HCV 
infection: it was found in 2%-15% of children with 
chronic infection[32,121-123] and LKM-1-positive children 
had a more advanced liver disease than LKM-1-
negative children[124]. In general, the pathogenetic role 
of NOSAs remains to be elucidated and autoantibodies 
do not predict liver fibrosis progression[125]. Despite the 
high prevalence of NOSAs, autoimmune diseases are 
rare in HCV infected children and adolescents[126]. 
In a series of 36 subjects, 4 had subclinical hypo-
thyroidism without antithyroid antibody and 2 anti-
thyiroglobulin antibody with normal TSH levels[127].
The presence of cryoglobulins and autoantibodies 
represents the chronic stimulation of the immune 
system by HCV by mechanisms such as molecular 
mimicry or interactions between the HCV E2 protein 
and CD81 molecule expressed by B-lymphocytes[128]. 
It must be underlined that sometimes cryoglobulins 
or NOSAs developed or persisted even after SVC[32], 
suggesting that HCV can elicit a chain of events within 
the immune system that can proceed independently 
from active viral replication. Whether this might give 
rise to significant morbidity even after SVC remains 
to be verified. On the other hand, HCV RNA has been 
detected in liver and/or in PBMCs of seropositive 
subjects after disappearance of serum/plasma 
viremia[128,129]. Furthermore, recent studies show that 
after successful interferon-based treatment, HCV 
traces are still detectable and this correlates with a 
peak of HCV-specific CTL response[130]. Therefore, this 
occult infection might be responsible for virus-induced 
immune reactions in sustained responders. HCV does 
not integrate into the host genome. Whether HCV 
persists in the liver in a form that is also refractory to 
eradication by successful direct acting antiviral agent 
(DAA) treatment has to be evaluated in long-term 
follow-up studies.
Anecdotally, other associations of chronic HCV 
infection and extrahepatic disorders have been described, 
such as diabetes[32,131], inflammatory myopathy[130], and 
opsoclonus-myoclonus syndrome[132]. 
CONCLUSION
HCV infection affects a large number of women of 
child-bearing age worldwide, and transmission of the 
virus from mother to child remains a serious public 
health problem. 
Several correlates of vertical transmission have 
been identified; however, none is modifiable and no 
interventions can prevent or reduce the transmission 
risk, with the exception of anti-HIV treatment in 
women with HIV/HCV co-infection. In particular, there 
is no reason to offer elective caesarean section or 
discourage lactation in infected mothers. The lack of 
effective preventive measures is not a contraindication 
for pregnancy; on the other hand, it makes useless 
the routine screening for the diagnosis of HCV infection 
in pregnant women. Invasive obstetric procedures 
favoring the contact with contaminated maternal blood 
should be avoided, though specific evidence is lacking.
The reduced reactivity of the immune system 
during pregnancy is presumably responsible for the 
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increased viral replication in the third trimester of 
gestation, a condition that might facilitate the virus 
transmission to the offspring. Despite the massive 
exposure of the fetus to viral particles and maternal 
HCV-infected PBMCs, the rate of MTCT is surprisingly 
low when compared to other viral infections, such 
as HIV-1, a further proof that different defensive 
mechanisms protect the offspring from distinct maternal 
viral infections. Further research is needed to better 
define these mechanisms and understand the innate 
and adaptive immune responses that regulate the 
host-virus interactions, so that new therapeutic 
strategies and preventive vaccines can be developed.
There is a clear association between maternal 
viral load and risk of HCV vertical transmission. An 
antiviral treatment during pregnancy in HCV RNA-
positive women is expected to reduce significantly the 
MTCT rate. Theoretically, the IFN-free and ribavirin-
free therapeutic regimens might represent an exciting 
perspective, because the new DAAs can give rise to 
a dramatic reduction in plasma HCV RNA level in few 
weeks[133]. However, at present they cannot be used in 
pregnant women, because any risk of toxic effects on 
the fetus must be excluded. Meanwhile, a significant 
decrease in vertical infections may derive, indirectly, 
from using these highly effective, pan-genotypic DAAs 
in infected women of child-bearing age. 
Spontaneous clearance of vertically acquired HCV 
infection occurs in at least one quarter of cases during 
childhood. Children with genotype 3 infection or 
polymorphisms of IL-28B gene locus or higher ALT 
levels in the first two years of life have greater chances 
of SVC. Since this mostly takes place in preschool age, 
postponing antiviral treatments beyond this age seems 
appropriate in the great majority of cases. 
Chronic infection is generally asymptomatic in childhood, 
although a low to moderate level of hepatomegaly and 
liver fibrosis may develop. Most infected children grow 
regularly and have a good quality of life. Occasionally, 
HCV can however progress, leading to severe liver 
disease or hepatic failure. Although the importance of 
a few viral or host factors are emerging, in the daily 
practice there are no reliable early prognostic markers. 
With the new drugs on the horizon, the possibility to 
better outline the natural history of vertically acquired 
HCV infection is waning. Who and when should be 
treated remains thus questionable. The answer is 
presumably every HCV infected child, provided that 
the ongoing trials confirm the safety and effectiveness 
of the new DAAs in children and, last but not least, 
their costs are affordable for a generalized use. 
The presence of NOSAs and cryoglobulins is frequent 
in HCV infected children and adolescents, whereas 
associated clinical manifestations are rare. Larger 
prospective studies possibly following children through 
the adult age are needed to clarify the influence of 
the vertical infection on the immune system and 
on the development of autoimmune diseases. The 
next availability of DAAs is expected to represent a 
paramount cornerstone for blocking not only the 
HCV-driven liver damage, but also the associated 
extrahepatic disorders.
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